-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Aeglea BioTherapeutics (NASDAQ:AGLE) Coverage Initiated by Analysts at StockNews.com
Aeglea BioTherapeutics (NASDAQ:AGLE) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a report published on Monday. The firm issued a hold rating on the biotechnology company's stock.
AGLE has been the subject of a number of other reports. Wells Fargo & Company upgraded shares of Aeglea BioTherapeutics from an equal weight rating to an overweight rating and boosted their price objective for the stock from $1.50 to $2.00 in a report on Friday, October 28th. Piper Sandler boosted their price target on Aeglea BioTherapeutics to $1.50 in a research note on Tuesday, November 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $1.88.
Get Aeglea BioTherapeutics alerts:Aeglea BioTherapeutics Trading Down 5.5 %
Aeglea BioTherapeutics stock opened at $0.48 on Monday. Aeglea BioTherapeutics has a 12 month low of $0.34 and a 12 month high of $4.54. The company has a market capitalization of $29.65 million, a price-to-earnings ratio of -0.42 and a beta of 1.66. The business's fifty day simple moving average is $0.54 and its two-hundred day simple moving average is $0.60.
Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. Aeglea BioTherapeutics had a negative net margin of 1,471.82% and a negative return on equity of 114.95%. The company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.63 million. On average, equities research analysts predict that Aeglea BioTherapeutics will post -1.01 EPS for the current year.Institutional Investors Weigh In On Aeglea BioTherapeutics
Large investors have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP lifted its holdings in shares of Aeglea BioTherapeutics by 76.9% during the 3rd quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company's stock valued at $216,000 after buying an additional 178,200 shares during the period. Ghost Tree Capital LLC boosted its position in Aeglea BioTherapeutics by 8.1% in the third quarter. Ghost Tree Capital LLC now owns 1,000,000 shares of the biotechnology company's stock worth $526,000 after purchasing an additional 75,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Aeglea BioTherapeutics by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company's stock valued at $600,000 after purchasing an additional 62,504 shares during the period. Nantahala Capital Management LLC increased its position in shares of Aeglea BioTherapeutics by 21.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock valued at $1,958,000 after purchasing an additional 676,718 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC lifted its stake in shares of Aeglea BioTherapeutics by 87.8% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock worth $2,701,000 after purchasing an additional 2,500,000 shares during the period. Institutional investors own 78.01% of the company's stock.
About Aeglea BioTherapeutics
(Get Rating)
Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
Read More
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a report published on Monday. The firm issued a hold rating on the biotechnology company's stock.
「證券新聞網」承擔對股份的覆蓋範圍 AEGLEA 生物治療學 (納斯達克:阿格爾 — 獲得評級) 在星期一發布的報告中。該公司對生物技術公司的股票發出了持有評級。
AGLE has been the subject of a number of other reports. Wells Fargo & Company upgraded shares of Aeglea BioTherapeutics from an equal weight rating to an overweight rating and boosted their price objective for the stock from $1.50 to $2.00 in a report on Friday, October 28th. Piper Sandler boosted their price target on Aeglea BioTherapeutics to $1.50 in a research note on Tuesday, November 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $1.88.
AGLE 一直是許多其他報告的主題。富國銀行公司將 Aeglea 生物治療藥物的股票從同等體重評級升級為超重評級,並在 10 月 28 日(星期五)的一份報告中將其股票的價格目標從 $1.50 提高到 2.00 美元。吹笛者桑德勒在 11 月 1 日(星期二)的一份研究報告中,將 Aeglea 生物治療學的價格目標提高到 1.50 美元。三位投資分析師對該股票進行了持有評級,其中三名分析師對該公司的股票給予了買入評級。根據 MarketBeat 的數據,該公司目前的平均評級為中等買入,平均目標價為 1.88 美元。
Aeglea BioTherapeutics Trading Down 5.5 %
AEGLEA 生物治療學交易下跌 5.5%
Aeglea BioTherapeutics stock opened at $0.48 on Monday. Aeglea BioTherapeutics has a 12 month low of $0.34 and a 12 month high of $4.54. The company has a market capitalization of $29.65 million, a price-to-earnings ratio of -0.42 and a beta of 1.66. The business's fifty day simple moving average is $0.54 and its two-hundred day simple moving average is $0.60.
安格勒生物治療股票週一以 0.48 美元開盤。埃格勒生物治療學的價格為 12 個月低點 0.34 美元,為 12 個月高點 4.54 美元。該公司的市值為 29.65 萬美元,價格與收益比為 -0.42,測試版為 1.66。該企業的五十天簡單移動平均線為 0.54 美元,其 200 天的簡單移動平均線為 0.60 美元。
Institutional Investors Weigh In On Aeglea BioTherapeutics
機構投資者權衡 Aeglea 生物治療學
Large investors have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP lifted its holdings in shares of Aeglea BioTherapeutics by 76.9% during the 3rd quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company's stock valued at $216,000 after buying an additional 178,200 shares during the period. Ghost Tree Capital LLC boosted its position in Aeglea BioTherapeutics by 8.1% in the third quarter. Ghost Tree Capital LLC now owns 1,000,000 shares of the biotechnology company's stock worth $526,000 after purchasing an additional 75,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Aeglea BioTherapeutics by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company's stock valued at $600,000 after purchasing an additional 62,504 shares during the period. Nantahala Capital Management LLC increased its position in shares of Aeglea BioTherapeutics by 21.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock valued at $1,958,000 after purchasing an additional 676,718 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC lifted its stake in shares of Aeglea BioTherapeutics by 87.8% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock worth $2,701,000 after purchasing an additional 2,500,000 shares during the period. Institutional investors own 78.01% of the company's stock.
大型投資者最近增加或減少了他們在股票中的股份。兩個西格瑪顧問 LP 在第三季度取消了艾格利亞生物治療學股份的持有量 76.9%。兩位西格瑪顧問 LP 現在擁有該生物技術公司股票的 409,900 股價值為 216,000 美元,在此期間購買了額外的 178,200 股股票。鬼樹資本有限責任公司在第三季度將其在 Aeglea 生物治療學的地位提高了 8.1%。鬼樹資本有限責任公司現在擁有 100 萬股生物技術公司的股票,價值 526,000 美元,在上一個季度購買了 75,000 股額外的 75,000 股。在第二季度,高盛集團在 Aeglea 生物治療的股份的股份增長了 5.6%。期內,高盛集團股份有限公司現在擁有該生物科技公司股票的 1,187,293 股,價值 60 萬美元。楠塔哈拉資本管理有限責任公司在第二季度增加了其在 Aeglea 生物治療學股份的地位 21.1%。南大哈拉資本管理有限責任公司現在擁有該生物技術公司股票的 3,877,311 股價值 1,958,000 美元,在上個季度額外購買 676,718 股股票後。最後,貝恩資本生命科學投資者有限責任公司在第二季度將其在 Aeglea 生物治療學股份的股份上升了 87.8%。貝恩資本生命科學投資者有限責任公司現在擁有 5,347,689 股價值 2,701,000 美元的生物技術公司股票在此期間額外購買 2,500,000 股股票後。機構投資者擁有公司股票的 78.01%。
About Aeglea BioTherapeutics
關於艾格列生物治療
(Get Rating)
(取得評分)
Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
Aeglea BioTheraptics, Inc 是一家臨床階段的生物技術公司,致力於開發下一代人類酵素療法,作為罕見和其他高負擔疾病的破壞性解決方案。其產品聚乙胺精氨酸酶正處於治療精氨酶 1 缺乏症的 3 期關鍵試驗中。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 獲取有關艾格勒生物療法研究報告的免費副本
- 為什麼黃金現在可以成為您的投資組合中閃閃發光的補充
- SoFi 技術打破收益,但要小心美聯儲決定
- 購買高露潔棕櫚樹的浸
- 馬倫汽車在招聘狂歡, 這可能意味著什麼?
- 數位互聯提出其收益指引
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Aeglea 生物治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Aeglea 生物治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧